Breast Cancer Action Says Two New Drug Pricing Studies Miss the Mark

Text Size: Normal / Medium / Large
Printer-friendly versionPrinter-friendly version

June 26, 2007

San Francisco, CA- Breast Cancer Action (BCA) today expressed grave concerns about the two new studies that purport to justify the exorbitantly high price of breast cancer drugs.

One of the studies looked at Herceptin-a drug that costs upwards of $40,000 a year. The other study looked at Aromasin-an aromatase inhibitor that costs more than $3000 per year in the United States .

Read more >>>